A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117



Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen, Takayuki Kosaka, Alison J Holmes, Andrew M Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E Johnson, Lewis C Cantley, Pasi A Jänne. Science 2007
Times Cited: 3347




List of shared articles



Times cited

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
0

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.
Julia Lai-Kwon, Crescens Tiu, Abhijit Pal, Sachin Khurana, Anna Minchom. Crit Rev Oncol Hematol 2021
3

Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer.
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J Peters, Omidreza Firuzi. Crit Rev Oncol Hematol 2021
3

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
2

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
Keunchil Park, Gee-Chen Chang, Giuseppe Curigliano, Wan-Teck Lim, Ross A Soo, Miguel A Molina-Vila, Valérie Cattan, Hélène Darville, Eric Gandossi, Veronika Smutna,[...]. Lung Cancer 2021
1

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Matthew Lee, Prantesh Jain, Feng Wang, Patrick C Ma, Alain Borczuk, Balazs Halmos. Expert Opin Ther Targets 2021
0

When the MET receptor kicks in to resist targeted therapies.
Marie Fernandes, Philippe Jamme, Alexis B Cortot, Zoulika Kherrouche, David Tulasne. Oncogene 2021
0

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.
Caroline E McCoach, Aiming Yu, David R Gandara, Jonathan W Riess, Daniel P Vang, Tiahong Li, Primo N Lara, Matthew Gubens, Frances Lara, Philip C Mack,[...]. JCO Precis Oncol 2021
1


Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
Victor Moreno, Richard Greil, Jeffrey Yachnin, Margarita Majem, Martin Wermke, Hendrik-Tobias Arkenau, Jean-Rene Basque, Prasanna Kumar Nidamarthy, Shruti Kapoor, Xiaoming Cui,[...]. Clin Ther 2021
0


Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R Joseph, Fiona Simpson. Cells 2021
2

HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence.
Jianjiang Fu, Xiaorui Su, Zhihua Li, Ling Deng, Xiawei Liu, Xuancheng Feng, Juan Peng. Oncogene 2021
1


Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.
Yiming Zhao, Shuyuan Wang, Zhengyu Yang, Yu Dong, Yanan Wang, Lele Zhang, Hai Hu, Baohui Han. Front Oncol 2021
0



Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.
Pınar Özden Eser, Raymond M Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M Haikala, Ciric To, Jeffrey J Okoro, Kshiti H Dholakia, Jihyun Choi,[...]. Sci Transl Med 2021
0

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.
Li Liu, Jingjing Qu, Jianfu Heng, Chunhua Zhou, Yi Xiong, Haiyan Yang, Wenjuan Jiang, Liang Zeng, Songlin Zhu, Yongchang Zhang,[...]. Front Oncol 2021
0

Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer.
V H F Lee, T S K Mok, Y Goto, V C C Hsue, L Yang, Y Jiang, D K C Leung, K S Lau, P Y Tse. Clin Oncol (R Coll Radiol) 2020
1

A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models.
John O DaSilva, Katie Yang, Andres E Perez Bay, Julian Andreev, Peter Ngoi, Erica Pyles, Matthew C Franklin, Drew Dudgeon, Ashique Rafique, Anthony Dore,[...]. Clin Cancer Res 2020
3


Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
92

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
41

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, Adam Langenbucher, Jessica J Lin, Marguerite M Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A Adams, Beow Y Yeap,[...]. Clin Cancer Res 2020
39


Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.
Xian Sun, Chia-Wei Li, Wei-Jan Wang, Mei-Kuang Chen, Hui Li, Yun-Ju Lai, Jennifer L Hsu, Paul B Koller, Li-Chuan Chan, Pei-Chih Lee,[...]. Am J Cancer Res 2020
5

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
M Schuler, R Berardi, W-T Lim, M de Jonge, T M Bauer, A Azaro, M Gottfried, J-Y Han, D H Lee, M Wollner,[...]. Ann Oncol 2020
26

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Jean-Pierre Delord, Guillem Argilés, Jerôme Fayette, Lori Wirth, Stefan Kasper, Salvatore Siena, Ricard Mesia, Rossana Berardi, Andrés Cervantes, Jeroen Dekervel,[...]. Invest New Drugs 2020
3

Progress on treatment of MET signaling pathway in non-small cell lung cancer.
Xiaoqing Yu, Sizhe Yu, Yun Fan. Int J Clin Oncol 2020
1


MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
27

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
19

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Yubo Wang, Panwen Tian, Lei Xia, Li Li, Rui Han, Mengxiao Zhu, Analyn Lizaso, Tian Qin, Min Li, Bing Yu,[...]. Lung Cancer 2020
5



Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd. Onco Targets Ther 2020
8

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Expert Opin Emerg Drugs 2020
3

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.
Marjorie Aubanel, Aurélie Swalduz, Virginie Avrillon, Louis Doublet, Bénédicte Mastroianni, Eve-Marie Neidhardt-Bérard, Maurice Pérol. Clin Lung Cancer 2020
1

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai-Xiang Hao, Angela Tam, Hui Qin Wang, Jinsheng Liang, Matthew T DiMare, Hyo-Eun Carrie Bhang, Youzhen Wang,[...]. Clin Cancer Res 2019
48

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
Ayesha Murtuza, Ajaz Bulbul, John Paul Shen, Parissa Keshavarzian, Brian D Woodward, Fernando J Lopez-Diaz, Scott M Lippman, Hatim Husain. Cancer Res 2019
67